HUNK Regulation of IL-4
IL-4 的 HUNK 调节
基本信息
- 批准号:10046490
- 负责人:
- 金额:$ 15.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:4T1AttenuatedBackBiological AssayBreast Cancer ModelBreast Cancer PatientCell physiologyCellsClinicalCyclic AMP-Dependent Protein KinasesDataDiseaseDown-RegulationEGF geneEnzyme-Linked Immunosorbent AssayEpidermal Growth Factor ReceptorExhibitsFlow CytometryHormonalHormone secretionImmuneImmune checkpoint inhibitorImmune responseImmunohistochemistryImmunotherapyImpairmentInterleukin-4MAPK3 geneMacrophage ActivationMammary NeoplasmsMammary glandMediatingMetastatic breast cancerModelingMolecularMonitorMusNeoplasm MetastasisParacrine CommunicationPhenotypePhosphorylationPhosphotransferasesProcessProductionReceptor SignalingRegulationSignal TransductionT-LymphocyteTestingTimeTumor-associated macrophagesVaccinesWestern Blottingbreast cancer progressioncell typecytokineepithelial to mesenchymal transitionin vivoknock-downmacrophagemalignant breast neoplasmmigrationmutantneoplastic cellnovelparacrinerecruitresponsesmall hairpin RNAtumortumor growthtumor microenvironment
项目摘要
PROJECT SUMMARY
Metastatic breast cancer is driven by pro-tumor immune responses. No immuno-agents are currently approved
for use in breast cancer and the ability of these agents to mitigate disease is currently unclear. Consequently,
developing a clear understanding of the mechanisms by which immune cells are regulated during breast cancer
progression is critical for the successful application of immunotherapy for breast cancer. We propose to evaluate
a protein kinase called Hormonally-upregulated Neu-associated Kinase (HUNK), a tumor and metastasis
promoting factor, as a target that alters immune response in metastatic breast cancer. Immune cells called tumor
associated macrophages (TAMs) are recruited to the tumor microenvironment through paracrine signaling with
tumor cells, which results in an immune suppressive phenotype and metastatic progression. Previous studies
show that TAMs exhibit an “alternatively” activated phenotype consistent with M2-type polarization and identify
IL-4 as a major cytokine that induces the M2-phenotype. We provide evidence that HUNK regulates IL-4
production in mammary tumor cells, which results in a reduction in TAMs in the tumor microenvironment. We
hypothesize that HUNK regulates IL-4 production in mammary tumor cells, which in turn, drives alternative
activation of macrophages (ie presence of TAMs) in the tumor microenvironment. These studies would be the
first to describe an immune related function for HUNK where tumor cell intrinsic signaling driven by HUNK
regulates paracrine signaling to TAMs.
项目摘要
转移性乳腺癌是由促肿瘤免疫反应驱动的。目前尚未批准免疫制剂
用于乳腺癌,这些药物减轻疾病的能力目前尚不清楚。因此,委员会认为,
对乳腺癌发生过程中免疫细胞的调节机制有了清晰的认识
进展对于成功应用乳腺癌免疫疗法至关重要。我们建议评估
一种称为激素上调的Neu-associated Kinase(HUNK)的蛋白激酶,
促进因子,作为改变转移性乳腺癌免疫反应的靶点。称为肿瘤的免疫细胞
相关巨噬细胞(TAM)通过旁分泌信号被招募到肿瘤微环境中,
肿瘤细胞,其导致免疫抑制表型和转移进展。以前的研究
显示TAM表现出与M2型极化一致“交替”活化表型,并鉴定出
IL-4作为诱导M2-表型的主要细胞因子。我们提供了HUNK调节IL-4的证据
在乳腺肿瘤细胞中产生,这导致肿瘤微环境中TAM的减少。我们
假设HUNK调节乳腺肿瘤细胞中IL-4的产生,这反过来又驱动了替代疗法,
肿瘤微环境中巨噬细胞的活化(即存在TAM)。这些研究将是
首先描述了HUNK的免疫相关功能,其中由HUNK驱动的肿瘤细胞内在信号传导
调节TAM的旁分泌信号。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth S. Yeh其他文献
Tetracycline-regulated mouse models of cancer.
四环素调节的癌症小鼠模型。
- DOI:
10.1101/pdb.top069823 - 发表时间:
2014 - 期刊:
- 影响因子:0
- 作者:
Elizabeth S. Yeh;Ann Vernon;H. Martin;L. Chodosh - 通讯作者:
L. Chodosh
PIN1, the cell cycle and cancer
PIN1、细胞周期与癌症
- DOI:
10.1038/nrc2107 - 发表时间:
2007-04-05 - 期刊:
- 影响因子:66.800
- 作者:
Elizabeth S. Yeh;Anthony R. Means - 通讯作者:
Anthony R. Means
Team building: a 3‐dimensional teamwork model
团队建设:三维团队合作模型
- DOI:
10.1108/13527590610687947 - 发表时间:
2006 - 期刊:
- 影响因子:0
- 作者:
Elizabeth S. Yeh;Charlene Smith;Claretha Jennings;Nancy Castro - 通讯作者:
Nancy Castro
Elizabeth S. Yeh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elizabeth S. Yeh', 18)}}的其他基金
Tumor cell -TAM Paracrine Signaling in Breast Cancer
乳腺癌中的肿瘤细胞 -TAM 旁分泌信号传导
- 批准号:
10583793 - 财政年份:2023
- 资助金额:
$ 15.85万 - 项目类别:
Overcoming Resistance in HER2-positive Breast Cancer
克服 HER2 阳性乳腺癌的耐药性
- 批准号:
9379089 - 财政年份:2015
- 资助金额:
$ 15.85万 - 项目类别:
Overcoming Resistance in HER2-positive Breast Cancer
克服 HER2 阳性乳腺癌的耐药性
- 批准号:
9044740 - 财政年份:2015
- 资助金额:
$ 15.85万 - 项目类别:
Overcoming Resistance in HER2-positive Breast Cancer
克服 HER2 阳性乳腺癌的耐药性
- 批准号:
9252410 - 财政年份:2015
- 资助金额:
$ 15.85万 - 项目类别:
Overcoming Resistance in HER2-positive Breast Cancer
克服 HER2 阳性乳腺癌的耐药性
- 批准号:
8882873 - 财政年份:2015
- 资助金额:
$ 15.85万 - 项目类别:
Overcoming Resistance in HER2-positive Breast Cancer
克服 HER2 阳性乳腺癌的耐药性
- 批准号:
9987996 - 财政年份:2015
- 资助金额:
$ 15.85万 - 项目类别:
Defining a role for Hunk in oncogenic signaling
定义 Hunk 在致癌信号传导中的作用
- 批准号:
7330026 - 财政年份:2007
- 资助金额:
$ 15.85万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 15.85万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 15.85万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 15.85万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 15.85万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 15.85万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 15.85万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 15.85万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 15.85万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 15.85万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 15.85万 - 项目类别:
Idea to Innovation